Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase NA 1Phase 2/3 1

Status

Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Glioblastoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Mouth Neoplasms 2Leukemia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hyperthermia 2

Interventions

pertuzumab 1Trastuzumab 1Docetaxel 1Carboplatin 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × HER2-positive Breast Cancer × Clear all
NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡